Since the definition of significant prostate cancer findings on biopsy, i.e. pathological and clinical findings that might predict metastasis and subsequently lead to disease-related mortality, has shifted and recently been re-assessed, previous PSA-based screening programs might not accurately represent modern practice. This evidence concerns the gene KLK3 and Familial prostate cancer.